← All trials
NCT03324932
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 25, 2017
- Primary completion
- Dec 31, 2019
- Completion date
- Dec 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 160
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kyoto Prefectural University of MedicineLead sponsor
- Kyoto Prefectural University of MedicineReponsible party - principal investigator
- Kyoto Prefectural University of MedicineStudy director
- Kyoto Prefectural University of MedicineOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.